GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Other Operating Expense

Neurocrine Biosciences (Neurocrine Biosciences) Other Operating Expense

: $0 Mil (TTM As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Neurocrine Biosciences's Other Operating Expense for the three months ended in Dec. 2023 was $-0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

Neurocrine Biosciences's quarterly Other Operating Expense increased from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then declined from Sep. 2023 ($0 Mil) to Dec. 2023 ($-0 Mil).

Neurocrine Biosciences's annual Other Operating Expense declined from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then increased from Dec. 2022 ($0 Mil) to Dec. 2023 ($0 Mil).


Neurocrine Biosciences Other Operating Expense Historical Data

The historical data trend for Neurocrine Biosciences's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Operating Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurocrine Biosciences Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080